Evolving concepts in the management of lobular neoplasia

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 4, Issue 5, 2006, Pages 511-522

  Anderson, Benjamin O ^a,b   Calhoun, Kristine E ^a,b   Rosen, Eric L ^a,b  

^a University of Washington ^*

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Atypical lobular hyperplasia; Breast cancer risk factor; Lobular carcinoma in situ; Premalignant lesion; Risk reduction

Indexed keywords

TAMOXIFEN;

ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CARCINOMA IN SITU; CHEMOPROPHYLAXIS; CLINICAL FEATURE; HISTOPATHOLOGY; HUMAN; LUNG CARCINOMA; MASTECTOMY;

EID: 33747592812     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2006.0041     Document Type: Article

References (71)

1. Foote FJ, Stewart F. Lobular carcinoma in situ: a rare form of mammary carcinoma. Am J Pathol 1941;17:491-496.
2. Carson W, Sanchez-Forgach E, Stomper P, et al. Lobular carcinoma in situ: observation without surgery as an appropriate therapy. Ann Surg Oncol 1994;1:141-146.
3. Cornil AV. Contributions a l'histoire du developpement histologique des tumeurs epitheliales (sqirrhe, encephaloide, etc.). J Anat Physiol 1865;2:266-276.
4. Ewing J. Neoplastic Diseases. Philadelphia: W.B. Saunders, 1919.
5. Cheatle GL, Cutler M. Tumours of the Breast. London, UK: Edward Arnold & Co.; 1931.
6. Broders AC. Carcinoma in situ contrasted with benign penetrating epithelium. JAMA 1932;99:1670-1674.
7. Godwin JT. Chronology of lobular carcinoma of the breast: report of a case. Cancer 1952;5:259-266.
8. Haagensen CD, Lane N, Lattes R, Bodian C. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer 1978;42:737-769.
9. Lakhani SR, Collins N, Sloane J, Stratton M. Loss of heterozygosity in lobular carcinoma in situ of the breast. J Clin Pathol (Mol Pathol) 1995;48:M74-M78.
10. Berx G, Cleton-Jansen AM, Strumane K, et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 1996;13:1919-1925.
11. Frost AR, Tsangaris TN, Silverberg SG. Pleomorphic lobular carcinoma in situ. Pathol Case Rev 1996;1:27-31.
12. Middleton L, Palacios D, Bryant B, et al. Pleomorphic lobular carcinoma: morphology, immunohistochemistry, and molecular analysis. Am J Surg Pathol 2000;24:1650-1656.
13. Rosen PP, Lieberman PH, Braun DWJ, et al. Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years. Am J Surg Pathol 1978;2:225-251.
14. Bodian CA, Perzin KH, Lattes R, et al. Prognostic significance of benign proliferative breast disease. Cancer 1993;7l:3896-3907.
15. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90: 1371-1388.
16. Carlson RW, Anderson BO, Burstein HJ, et al. NCCN Breast Cancer Clinical Practice Guidelines in Oncology. J Natl Compr Cane Netw 2005;3:238-289.
17. Andersen J, Vendelboe M. Cytoplasmic mucous globules in lobular carcinoma in situ. Diagnosis and prognosis. Am J Surg Pathol 1981;5: 251-255.
18. Barwick K, Kashgarian M, Rosen P. "Clear cell" change within duct and lobular epithelium of the human breast. Parhol Annu 1982;17:319-328.
19. Breslow A, Brancaccio M. Intracellular mucin production by lobular breast carcinoma cells. Arch Pathol Lab Med 1976; 100:620-621.
20. Eusebi V, Betts C, Haagensen D, et al. Apocrine differentiation in lobular carcinoma of the breast: a morphologic, immunologic and ultrastructural study. Hum Pathol 1984;15:134-140.
21. Gad A, Azzopardi J. Lobular carcinoma of the breast: a special variant of mucin-secreting carcinoma. J Clin Pathol 1975;28: 711-716.
22. Rosen P. Lobular carcinoma and hyperplasia. In: Rosen P, ed. Breast Pathology. Philadelphia: Lippmcott-Raven; 1997:507-544.
23. Acs G, Lawton T, Rebbeck T, et al. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol 2001;115: 85-98.
24. Bentz J, Yassa N, Clayton F. Pleomorphic lobular carcinoma of the breast: clinicopathologic features of 12 cases. Modern Pathol 1998;11:814-822.
25. Bodis S, Siziopikou KP, Schnitt SJ, et al. Extensive apoptosis in ductal carcinoma in situ of the breast. Cancer 1996;77:1831-1935.
26. Jacobs T, Pliss N, Kouria G, Schnitt S. Carcinomas in situ of the breast with indeterminate features: role of E-cadherin staining in categorization. Am J Surg Pathol 2001;25:229-236.
27. Malut H, Swanson P, Koerner F. Solid low-grade in situ carcinoma of the breast: role of associated lesions and E-cadherin in differential diagnosis. Am J Surg Pathol 2001;25:237-244.
28. Schnitt S, Morrow M. Lobular carcinoma in situ: current concepts and controversies. Semin Diagn Pathol 1999;16:209-223.
29. Tavassoli F. Lobular neoplasia. In: Tavassoli F, ed. Pathology of the Breast, 2nd ed. Stamford: Appleton & Lange; 1999:373-400.
30. Sapino A1 Frigerio A, Peterse J, et al. Mammographically detected in situ lobular carcinoma of the breast. Virchows Arch 2000;436: 421-430.
31. Fisher ER, Costantino J, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Five-year observations concerning lobular carcinoma in situ. Cancer 1996;78:1403-1416.
32. De Leeuw W, Berx G, Vos C, et al. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol 1997;183:404-411.
33. Gamallo C, Palacios J, Suarez A, et al. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am J Pathol 1993;142:987-993.
34. Kanai Y, Oda T, Tsuda H, et al. Point mutation of the E-cadherin gene in invasive lobular carcinoma of the breast. Jpn J Cancer Res 1994;85:1035-1039.
35. Moll R, Mitze M, Frixen U, Birchmeier W. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol 1993;143:1731-1742.
36. Vos C, Cleton-Jansen A, Berx G, et al. E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer 1997;76:1131-1133.
37. Gupta S, Douglas-Jones A, Jasani B, et al. E-cadherin (E-cad) expression in duct carcinoma in situ (DCIS) of the breast. Virchows Arch 1997;430:23-28.
38. Kashiwaba M, Tamura G, Suzuki Y, et al. Epithelial-cadherin gene is not mutated in ductal carcinomas of the breast. Jpn J Cancer Res 1995;86:1054-1059.
39. Lishman S, Lakhani S. Atypical lobular hyperplasia and lobular carcinoma in situ: surgical and molecular pathology. Histopathology 1999;35:195-200.
40. Li CI, Anderson BO, Daling JR, Moe RE. Changing incidence of lobular carcinoma in situ of the breast. Breast Cancer Res Treat 2002;75:259-268.
41. Anderson BO, Li CI, Lawton TJ, et al. Clinical management of lobular carcinoma in situ. In: Singletary SE, Robb GL, Hortobagyi GN, eds. Advanced Therapy of Breast Disease, 2nd ed. Hamilton, Ontario, Canada: B.C. Decker; 2004:269-280.
42. Li CI, Weiss NS, Stanford JL, Daling JR. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 2000;88:2570-2577.
43. Georgian-Smith D, Lawton TJ. Calcifications of lobular carcinoma in situ of the breast: radiologic-pathologic correlation. Am J Roentgenol 2001;176:1255-1259.
44. Muir J. The evolution of carcinoma of the mamma. J Pathol Bacteriol 1941;52:155-172.
45. Rosen PP, Senie R, Schottenfeld D, Ashikari R. Noninvasive breast carcinoma: frequency of unsuspected invasion and implications for treatment. Ann Surg 1979;189:377-382.
46. Swain SM. Overview and treatment of lobular carcinoma in situ. In: Silverstein MJ, ed. Ductal carcinoma in situ of the breast. Baltimore: Williams & Wilkins; 1997:595-609.
47. Beute BJ, Kalisher L, Hutter RVP. Lobular carcinoma in situ of the breast: clinical, pathologic and mammographic features. Am J Roentgenol 1991;157:257-265.
48. Page DL, Kidd TE Jr, Dupont WD, et al. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol 1991;22:1232-1239.
49. Haagensen CD. Lobular neoplasia (lobular carcinoma in situ). In: Haagensen CD, ed. Diseases of the Breast. Philadelphia: WB. Saunders; 1986:192-241.
50. Anderson JA. Multicentric and bilateral appearance of lobular carcinoma in situ of the breast. Acta Pathol Microbiol Scand [A] 1974;82:730-734.
51. Wheeler JE, Enterline HT, Roseman JM, et al. Lobular carcinoma in situ of the breast: long-term followup. Cancer 1974;34: 554-563.
52. Eusebi V, Magalhaes F, Azzopardi JG. Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation. Human Pathol 1992;23:655-662.
53. Weidner N, Semple JP. Pleomorphic variant of invasive lobular carcinoma of the breast. Hum Pathol 1992;23:1167-1171.
54. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group [see comments]. Lancet 1998;351:1451-1467.
55. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352: 98-101.
56. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study [see comments]. Lancet 1998;352: 93-97.
57. Anderson BO, Lawton TJ, Rinn K, et al. Lobular carcinoma in situ. In: Silverstein MJ, ed. Ductal Carcinoma In Situ of the Breast, 2nd ed. Philadelphia: Lippincott Williams and Wilkins; 2002: 615-634.
58. Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol 1999;17:1939-1955.
59. O'Driscoll D, Britton P, Bobrow L, et al. Lobular carcinoma in situ on core biopsy-what is the clinical significance? Clin Radiol 2001;56:216-220.
60. Liberman L, Sama M, Susnik B, et al. Lobular carcinoma in situ at percutaneous breast biopsy: surgical biopsy findings [see comments]. AJR Am J Roentgenol 1999;173:291-299.
61. Middleton LP, Grant S, Stephens T, et al. Lobular carcinoma in situ diagnosed by core needle biopsy: when should it be excised? Mod Pathol 2003;16:120-129.
62. Foster MC, Helvie MA, Gregory NE, et al. Lobular carcinoma in situ or atypical lobular hyperplasia at core-needle biopsy: is excisional biopsy necessary? Radiology 2004;231:813-819.
63. Carlson RW, Anderson BO, Bonaccio E, et al. NCCN Breast Cancer Screening and Diagnosis Clinical Practice Guidelines in Oncology 1.2004. Complete Library of NCCN Clinical Practice Guidelines in Oncology CD-ROM. Jenkintown, PA: National Comprehensive Cancer Network; 2005. To view the most recent version of the guidelines, go to www.nccn.org.
64. Moran M, Haffty BG. Lobular carcinoma in situ as a component of breast cancer: the long-term outcome in patients treated with breast-conservation therapy. Int J Radiat Oncol Biol Phys 1998; 40:353-358.
65. Abner AL, Connolly JL, Recht A, et al. The relation between the presence and extent of lobular carcinoma in situ and the risk of local recurrence for patients with infiltrating carcinoma of the breast treated with conservative surgery and radiation therapy. Cancer 2000;88:1072-1077.
66. Fowble B, Hanlon AL, Patchefsky A, et al. The presence of proliferative breast disease with atypia does not significantly influence outcome in early-stage invasive breast cancer treated with conservative surgery and radiation. Int J Radiat Oncol Biol Phys 1998;42:105-115.
67. Sasson AR, Fowble B, Hanlon AL, et al. Lobular carcinoma in situ increases the risk of local recurrence in selected patients with stages I and II breast carcinoma treated with conservative surgery and radiation. Cancer 2001;91:1862-1869.
68. Lehman CD, Blume JD, Weatherall P, et al. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer 2005;103:1898-1905.
69. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340:77-84.
70. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999; 353:1993-2000.
71. Fisher B, Land S, Mamounas E, et al. Prevention of invasive hreast cancer in women with ductal carcinoma in situ: an update ot the National Surgical Adjuvant Breast and Bowel Project experience. In: Silverstein MJ, ed. Ductal carcinoma in situ of the breast. 2nd ed. Philadelphia: Lippincott Williams and Wilkins, 2002: 432-446.